Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. by Robert, Lidia et al.
UCLA
UCLA Previously Published Works
Title
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing 
TCR usage in blood lymphocytes.
Permalink
https://escholarship.org/uc/item/8hw15134
Journal
Oncoimmunology, 3(6)
ISSN
2162-4011
Authors
Robert, Lidia
Harview, Christina
Emerson, Ryan
et al.
Publication Date
2014
DOI
10.4161/onci.29244
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
 Author's View
www.landesbioscience.com oncoimmunology e29244-1
oncoimmunology 3, e29244; June 2014; © 2014 Landes Bioscience
Author's View
Immune checkpoint blockade con-
tinues to transform cancer therapy and 
outcomes. These new agents can achieve 
long-lasting responses and potentially cure 
selected patients with metastatic cancers. 
Blockade of cytotoxic T-lymphocyte-
associated protein 4 (CTLA4) was the first 
immunotherapy to show durable clinical 
responses.1,2 Although response occurred 
in less than 15% of patients, the new 
therapy showed promise and produced 
excitement within the medical commu-
nity. More recently, Phase I clinical trials 
with antibodies blocking the programmed 
cell death-1 (PDCD1, better known as 
PD-1) receptor has produced responses 
in 20–40% of patients with melanoma, 
renal, and non-small cell lung cancer.3,4 
Many patients even experience continued 
regression after discontinuation of treat-
ment.5 This is a significant improvement 
in response rate and durability of response 
when compared with other common 
therapies such as targeted therapies and 
chemotherapy.
Our group has been engaged in explor-
ing these immune checkpoint blockade 
mechanisms since the first agents were 
developed.6,7 In our most recent article, 
CTLA4 blockade broadens the peripheral 
T cell receptor repertoire,8 we used high-
throughput deep sequencing of the TCR 
V-β CDR3 region to better characterize 
the expansion and clonality of the T-cell 
repertoire.9 Our approach was to study 
the effects of CTLA4 blockade in periph-
eral blood mononuclear cells (PBMCs). 
Previously, we had intended to use this 
technology to further study the tumoral 
infiltrating lymphocytes (TILs) from for-
malin-fixed paraffin-embedded (FFPE) 
tissue blocks. However, this was techni-
cally challenging because whole genome 
amplification (WGA) was required after 
microdissection of the tumoral area due to 
low yield of genomic DNA. Unfortunately, 
this technique introduced artifacts into 
our results rendering them unreliable 
for interpretation. We next switched to 
peripheral blood to extract genomic DNA 
from patients with metastatic melanoma 
to comparatively examine the TCR reper-
toire at baseline (day 0) and after 30 to 
60 d of treatment, including 21 patients 
treated with tremelimumab. At the same 
time, we extracted genomic DNA from 
4 healthy donors at baseline and after 
3 mo to use them as controls for back-
ground changes in TCR usage among cir-
culating T cells in the blood.
More recently, we have been able to 
get data for a new pool of 9 paired (before 
and after treatment) peripheral blood 
samples from melanoma patients treated 
with PD-1 blockade (MK-3475, pembro-
lizumab). These results were presented at 
the 2014 annual meeting of the American 
Association for Cancer Research (AACR), 
San Diego, CA, USA, and are included 
in this brief report. The in-frame result-
ing sequences were analyzed in terms of 
richness (number of unique productive 
sequences) and Shannon index (diversity 
index). For the healthy donors, results 
showed random changes without signifi-
cance (P = 0.93 and P = 0.68 for richness 
and Shannon index, respectively). On the 
other hand, as shown in Figure 1, we found 
that patients treated with CTLA4 blockade 
experienced a significant increase in the 
number and complexity of TCR variants, 
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targeting immune inhibitory receptors has brought excitement, innovation and hope to cancer patients. our recent 
work revealed the immunological effects of blocking the CtLA4 and PD-1 immune checkpoints on t cell receptor usage 
among peripheral blood cells, and further uncovers how the expansion of the t cell repertoire matches the immunotoxic-
ity profile of the therapy.
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attributable to drug treatment (P = 0.001 
and P = 0.04 respectively). This increase 
was not reproduced in the 9 paired sam-
ples from patients treated with MK-3475 
(P = 0.15 and P = 0.56 respectively; 
Figure 1). Four clinical responders out of 
21 patients treated with CTLA4 blockade 
exhibited an increase in TCR richness. In 
the case of PD-1 blockade (MK-3475), 
responders showed both increase in rich-
ness (one out of nine) and decrease in rich-
ness (two out of nine) indifferently.
Our results are suggestive of differing 
immunological effects of these two agents 
on circulating T cells. The expansion of 
TCR usage in samples treated with anti-
CTLA4 immunotherapy goes together 
with the priming encounter that takes 
place between T cells and antigen pre-
senting cells (APCs) in the lymph node. 
CTLA4 blockade allows this interaction 
to occur without coinhibitory signals 
and can lead to T-cell proliferation and 
non-specific T-cell activation. For PD-1 
blockade the context is different, since this 
coinhibitory signal occurs between previ-
ously primed T cells resident in peripheral 
tissues, in this case in tumor lesions.10 
Targeting this restricted subtype of T cells 
enriched for tumor antigen specificity, 
also explains why an immunotoxicity pro-
file is less frequent with PD-1 blockade in 
comparison to CTLA4 blockade. As we 
move toward the initiation of combination 
therapies, and, as new immune check-
point inhibiting agents are being tested 
in the clinic, it is important to continue 
elucidating their mechanism of action in 
the peripheral blood and intratumoral 
environments.
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Figure 1. immunotherapy-specific changes in the absolute number of unique t cell receptor 
sequences in cancer patient blood lymphocytes. Changes in the t cell receptor (tCr) usage 
among circulating t cells in the peripheral blood reported between baseline (day 0) and 30 to 60 
d following treatment. Data shown are from 21 patients with metastatic melanoma treated with 
the CtLA-4 blocking antibody tremelimumab (GA, in black), nine with the PD-1 blockade agent 
MK-3475 (MK, in gray) and four healthy donors (hD, in white).
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